Loading clinical trials...

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL | Clinical Trials | Clareo Health

UNKNOWNEARLY_PHASE1

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

NCT04412174•Hebei Yanda Ludaopei Hospital

Summary

The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-NHL. The investigators plan to include 18 subjects to receive GC022F therapy.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Aged 18-70 years;
•2. Relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL): 1) Chemotherapy-refractory disease, defined as one or more of the following: a) No response to first-line therapy (primary refractory disease, subjects who are intolerant to first-line therapy chemotherapy are excluded): i. PD as the best response to first-line therapy; ii.SD as the best response after at least 4 cycles of first-line therapy (e.g., 4 cycles of R-CHOP) with SD duration no longer than 6 months from last dose of therapy; b) No response to second or greater lines of therapy: i. PD as the best response to most recent therapy regimen; ii. SD as the best response after at least 2 cycles of last line of therapy with SD duration no longer than 6 months from last dose of therapy; c) Refractory post-ASCT(autologous stem cell transplantation): i. Disease progression or relapsed ≤12 months of ASCT (must have biopsy proven recurrence in relapsed subjects); ii. If salvage therapy is given post-ASCT, the subject must have had no response to or relapsed after the last line of therapy; d) PD or SD as the best response after previous CAR-T therapy (at least 3 months ago); 2) Subjects must have received adequate prior therapy including at a minimum: anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative, and an anthracycline containing chemotherapy regimen; for subjects with transformed FL must have received prior chemotherapy for follicular lymphoma and subsequently have chemotherapy-refractory disease after transformation to DLBCL; 3) At least 1 measurable lesion according to the Lugano Response Criteria (Cheson 2014). Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy: a) For nodular lesions, longest diameter ≥15mm, no requirement for shortest diameter; b) For extranodal lesions (lesions other than lymph node and nodular lesions, including liver and spleen), longest diameter ≥10mm, no requirement for shortest diameter;
•3. ECOG performance status ≤2 score;
•4. Life expectancy≥12 weeks;
•5. CD19 and/or CD22 positive expression demonstrated in tumor tissue;
•6. Adequate organ function defined as: 1) Creatinine clearance (as estimated by Cockcroft Gault method)\>60 mL/min; for male, creatinine clearance=\[ (140-age)×weight(kg)\]/\[0.818×creatinine (μmol/L)\] ; for female, creatinine clearance =\[(140-age)×weight(kg)×0.85\]/\[0.818×creatinine (μmol/L)\]; 2) Serum ALT/AST\<2.5×ULN (for subjects with liver metastases, ALT/AST≤5×ULN); 3) Total bilirubin\<1.5×ULN (for subjects with Gilbert's syndrome, total bilirubin≤ 3×ULN); 4) Left ventricular ejection fraction (LVEF)\>50%, no evidence of clinically significant pericardial effusion as determined by an ECHO; 5) No clinically significant pleural effusion; 6) Baseline oxygen saturation \>92% on room air;
•7. Females of reproductive age must be in non-lactation period. Females of childbearing potential must have a negative hypersensitive serum pregnancy test. All subjects must use medical-approved-contraception (such as intrauterine device and contraceptive drugs) during the period of treatment and in 2 years after CAR-T infusion; males should avoid sperm donation;
•8. Venous access can be established, peripheral blood mononuclear cells (PBMC) can be collected in researcher's judgement;
•9. Agrees to sign informed consent form;
•10. Be able to make good communication with researchers, willing and able to comply with the planned visit, complete the research according to regulations.

Exclusion Criteria

•1. Gastrointestinal involvement;
•2. Active central nervous system (CNS) involvement;
•3. Concomitant malignancy other than: cured non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ, other malignancy whose disease-free survival exceeds 5 years;
•4. Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb positive with HBV DNA copies positive; TPPA;
•5. Live vaccine ≤4 weeks prior to enrollment;
•6. Autologous stem cell transplantation (ASCT) ≤6 weeks prior to enrollment, history of allogeneic hematopoietic stem cell transplantation (allo-HSCT);
•7. Presence of complication that require systemic corticosteroids or other immunosuppressive drugs therapy during the trial in researcher's judgement;
•8. CNS stereotactic radiotherapy ≤4 weeks prior to enrollment;
•9. Toxicities related to previous therapy did not relieved to ≤1 grade, except hematological toxicity and alopecia;
•10. Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or presence of other intolerant conditions, or severe allergic constitution;
+6 more criteria

Locations (1)

Hebei Yanda Ludaopei Hospital

Sanhe, Hebei, China

Key Dates

Start Date

June 1, 2020

Primary Completion Date

December 1, 2022

Completion Date

December 1, 2022

Last Updated

June 2, 2020

Enrollment

ESTIMATED participants

Conditions

B-cell Non Hodgkin Lymphoma

Interventions

GC022F

BIOLOGICAL

Contacts

Peihua Lu, PhD&MD

CONTACT

+86-0316-3306393 Peihua_lu@126.com

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

NCT06365671

B-cell Non Hodgkin Lymphoma

View study

RECRUITINGPHASE1

Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL

NCT06707259

B-cell Non Hodgkin Lymphoma

View study

RECRUITINGPHASE1

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 2, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

Inclusion Criteria

Exclusion Criteria

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

MargheRITA (Remote Intelligence for Therapeutic Adherence)

Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL